Ryosuke Desaki1, Genta Sawada2, Hiroshi Okumura3, Ryuji Ikeda4, Kan Tanabe1, Hisateru Komatsu2, Koshi Mimori2, Masaki Mori5, Yoshiaki Kita1, Yasuto Uchikado1, Takaaki Arigami1, Yoshikazu Uenosono1, Tetsuhiro Owaki6, Sumiya Ishigami1, Shoji Natsugoe1. 1. Department of Surgical Oncology, Digestive Surgery, Graduate School of Medical Sciences, Kagoshima University, Kagoshima, Japan. 2. Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan. 3. Department of Surgical Oncology, Digestive Surgery, Graduate School of Medical Sciences, Kagoshima University, Kagoshima, Japan. hokumura@m.kufm.kagoshima-u.ac.jp. 4. Department of Clinical Pharmacy and Pharmacology, Graduate School of Medicine, Kagoshima University, Kagoshima, Japan. 5. Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Osaka University, Suita, Osaka, Japan. 6. Education Center for Doctors in Remote Islands and Rural Areas, Graduate School of Medical Sciences, Kagoshima University, Kagoshima, Japan.
Abstract
BACKGROUND: Cysteine/histidine-rich 1 (CYHR1) was first discovered in a yeast two-hybrid screen with murine galectin-3, and no previous reports have described a relationship between the CYHR1 gene and human cancer. The current study evaluated the role and significance of CYHR1 in esophageal cancer. METHODS: The human esophageal squamous cell carcinoma (ESCC) cell line TE-8 and the CYHR1 knock-down cell line TE-8/small interfering (si)-CYHR1 were used for in vitro and in vivo assays. For clinical study, ESCC tissues (n = 104) were used. RESULTS: Compared with parental cells, TE-8/si-CYHR1 cells had suppressed proliferation and invasion activities. In the in vivo assay, the tumors from TE-8 cells treated with si-CYHR1 had abrogated tumorigenicity. In the clinical study, the expression of CYHR1 mRNA was associated with lymph node metastasis and stage and shown to be an independent prognostic factor. CONCLUSIONS: As the findings show, CYHR1 may represent not only a valuable prognostic marker but also a therapeutic target for ESCC patients.
BACKGROUND:Cysteine/histidine-rich 1 (CYHR1) was first discovered in a yeast two-hybrid screen with murinegalectin-3, and no previous reports have described a relationship between the CYHR1 gene and humancancer. The current study evaluated the role and significance of CYHR1 in esophageal cancer. METHODS: The humanesophageal squamous cell carcinoma (ESCC) cell line TE-8 and the CYHR1 knock-down cell line TE-8/small interfering (si)-CYHR1 were used for in vitro and in vivo assays. For clinical study, ESCC tissues (n = 104) were used. RESULTS: Compared with parental cells, TE-8/si-CYHR1 cells had suppressed proliferation and invasion activities. In the in vivo assay, the tumors from TE-8 cells treated with si-CYHR1 had abrogated tumorigenicity. In the clinical study, the expression of CYHR1 mRNA was associated with lymph node metastasis and stage and shown to be an independent prognostic factor. CONCLUSIONS: As the findings show, CYHR1 may represent not only a valuable prognostic marker but also a therapeutic target for ESCC patients.